Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06835919 in Healthy Japanese Adults
NCT04427917Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) comparing PF-06835919 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at Day 42, Number of Participants With Clinical Laboratory Findings of Potential Clinical Importance at Day 10 and 6 more. Started Nov 2020; status: completed.
02
Drugs
PF-06835919
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04427917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427917.